{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    18,
    19,
    20,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28,
    29
  ],
  "modelUsed": "gemini-3-flash-preview",
  "advanced": {
    "studyAmendments": [
      {
        "id": "amend_1",
        "number": "1",
        "name": "Amendment 1",
        "scope": {
          "id": "f303864d-1611-4f58-acd9-73813a7140c8",
          "code": "Global",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Global",
          "instanceType": "Code"
        },
        "primaryReason": {
          "id": "852a2aeb-8357-4522-afb1-8963bc65c1d6",
          "code": {
            "id": "8c209121-4497-47ae-abca-2eea09c6c44b",
            "code": "C98782",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Protocol Amendment",
            "instanceType": "Code"
          },
          "otherReason": "Protocol Amendment",
          "instanceType": "StudyAmendmentReason"
        },
        "geographicScopes": [
          {
            "id": "3e945cfa-0a9a-4cac-b90e-3833ef3a8827",
            "type": {
              "id": "5e22f75e-b552-401a-8e2a-38f7532761af",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "instanceType": "GeographicScope"
          }
        ],
        "instanceType": "StudyAmendment",
        "summary": "Added editorial changes throughout the document to improve clarity and to correct typographic errors. Revised the Protocol Summary and Schedule of Activities to expand the age range for Cohort 1 to include subjects 65 years of age and older. Added flexibility to clinical assessment wording, increased the number of study subjects, and added potential for investigator sites in Europe.",
        "effectiveDate": "2018-09-25",
        "reasonIds": [
          "ar_1_1",
          "ar_1_2",
          "ar_1_3"
        ],
        "previousVersion": "Original Protocol",
        "newVersion": "Amendment 1"
      },
      {
        "id": "amend_2",
        "number": "2",
        "name": "Amendment 2",
        "scope": {
          "id": "dadcde69-92e9-4cd4-916e-e849af650331",
          "code": "Global",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Global",
          "instanceType": "Code"
        },
        "primaryReason": {
          "id": "f537e731-6fb4-4717-a28b-ffc0e12b07a1",
          "code": {
            "id": "5f066d4c-a585-478e-839b-7d197c8195ad",
            "code": "C98782",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Protocol Amendment",
            "instanceType": "Code"
          },
          "otherReason": "Protocol Amendment",
          "instanceType": "StudyAmendmentReason"
        },
        "geographicScopes": [
          {
            "id": "91205a80-0503-4a76-8b67-8bda12c18014",
            "type": {
              "id": "847afd37-26e3-4eed-b604-2070059aa17a",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "instanceType": "GeographicScope"
          }
        ],
        "instanceType": "StudyAmendment",
        "summary": "Section 1.3: Added benefit-risk assessment (country specific-amendment, required for Sweden by the Swedish Medical Products Agency [MPA]). European Clinical Trials Database (EudraCT) Number: Updated to 2018-004279-11.",
        "effectiveDate": "2019-02-11",
        "reasonIds": [
          "ar_2_1"
        ],
        "previousVersion": "Amendment 1",
        "newVersion": "Amendment 2"
      }
    ],
    "amendmentReasons": [
      {
        "id": "ar_1_1",
        "code": "SCIENTIFIC",
        "description": "Scientific",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_1_2",
        "code": "OPERATIONAL",
        "description": "Operational",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_1_3",
        "code": "ADMINISTRATIVE",
        "description": "Administrative",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_2_1",
        "code": "REGULATORY",
        "description": "Regulatory",
        "instanceType": "AmendmentReason"
      }
    ],
    "countries": [
      {
        "id": "country_1",
        "name": "United States",
        "instanceType": "Country",
        "code": "US"
      },
      {
        "id": "country_2",
        "name": "Sweden",
        "instanceType": "Country",
        "code": "SE"
      }
    ],
    "studySites": [],
    "summary": {
      "amendmentCount": 2,
      "countryCount": 2,
      "siteCount": 0
    },
    "geographicScope": {
      "id": "geo_1",
      "name": "Study Geographic Scope",
      "scopeType": "Global",
      "instanceType": "GeographicScope",
      "countryIds": [
        "country_1",
        "country_2"
      ],
      "regions": [
        "North America",
        "Europe"
      ]
    }
  },
  "rawResponse": {
    "amendments": [
      {
        "number": "1",
        "effectiveDate": "2018-09-25",
        "summary": "Added editorial changes throughout the document to improve clarity and to correct typographic errors. Revised the Protocol Summary and Schedule of Activities to expand the age range for Cohort 1 to include subjects 65 years of age and older. Added flexibility to clinical assessment wording, increased the number of study subjects, and added potential for investigator sites in Europe.",
        "previousVersion": "Original Protocol",
        "newVersion": "Amendment 1",
        "reasons": [
          "Scientific",
          "Operational",
          "Administrative"
        ]
      },
      {
        "number": "2",
        "effectiveDate": "2019-02-11",
        "summary": "Section 1.3: Added benefit-risk assessment (country specific-amendment, required for Sweden by the Swedish Medical Products Agency [MPA]). European Clinical Trials Database (EudraCT) Number: Updated to 2018-004279-11.",
        "previousVersion": "Amendment 1",
        "newVersion": "Amendment 2",
        "reasons": [
          "Regulatory"
        ]
      }
    ],
    "geographicScope": {
      "type": "Global",
      "countries": [
        {
          "name": "United States",
          "code": "US"
        },
        {
          "name": "Sweden",
          "code": "SE"
        }
      ],
      "regions": [
        "North America",
        "Europe"
      ],
      "plannedSites": null
    },
    "sites": []
  }
}